Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Eli Lilly and Company (NYSE: LLY) is one of the best long term low volatility stocks to buy now. In a report released on July ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In the past five years, ...

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.